Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,309 INR | -0.74% | +1.65% | +17.58% |
11:35am | Makers Laboratories Gets Board Nod to Sell Mumbai, India Property to Ipca Laboratories | MT |
Mar. 29 | Ipca Laboratories Limited Announces Cessation of Anand T. Kusre as an Independent Director | CI |
Summary
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- With an expected P/E ratio at 50.69 and 34.78 respectively for both the current and next fiscal years, the company operates with high earnings multiples.
- With an enterprise value anticipated at 4.52 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- The company is not the most generous with respect to shareholders' compensation.
- The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
- Financial statements have repeatedly disappointed market stakeholders. Most often, they were below expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+17.58% | 4.02B | C+ | ||
+39.80% | 723B | C+ | ||
+34.28% | 595B | B | ||
-3.63% | 369B | C+ | ||
+20.25% | 332B | B- | ||
+2.86% | 282B | C+ | ||
+17.02% | 244B | B+ | ||
+9.31% | 208B | B- | ||
-5.07% | 205B | A+ | ||
+0.02% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- IPCALAB Stock
- Ratings Ipca Laboratories Limited